Modified peptides as therapeutic agents

Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C435S069500, C435S069100, C435S091100, C530S351000, C530S350000, C530S324000, C536S023400

Reexamination Certificate

active

07488590

ABSTRACT:
Pharmacologically active compounds are prepared by (a) selecting at least one peptide that modulates the activity of AGP-3, (b) preparing a gene construct that comprises at least one said selected sequence, and (c) expressing the pharmacologically active compound in which an Fc domain is covalently linked to the selected peptide. The pharmacologic agent can be expressed inE. coli.

REFERENCES:
patent: 5223409 (1993-06-01), Ladner et al.
patent: 5338665 (1994-08-01), Schatz et al.
patent: 5432018 (1995-07-01), Dower et al.
patent: 5480981 (1996-01-01), Goodwin et al.
patent: 5498530 (1996-03-01), Schatz et al.
patent: 5514582 (1996-05-01), Capon et al.
patent: 5608035 (1997-03-01), Yanofsky et al.
patent: 5733731 (1998-03-01), Schatz et al.
patent: 5739277 (1998-04-01), Presta et al.
patent: 5767234 (1998-06-01), Yanofsky et al.
patent: 5773569 (1998-06-01), Wrighton et al.
patent: 5786331 (1998-07-01), Barrett et al.
patent: 5869451 (1999-02-01), Dower et al.
patent: 5869452 (1999-02-01), Ng et al.
patent: 5877151 (1999-03-01), Pereira
patent: 5880096 (1999-03-01), Barrett et al.
patent: 5922545 (1999-07-01), Mattheakis et al.
patent: 5932546 (1999-08-01), Barrett et al.
patent: 5945507 (1999-08-01), Montelaro
patent: 5969102 (1999-10-01), Bram et al.
patent: 6323323 (2001-11-01), Sledziewski et al.
patent: 6331415 (2001-12-01), Cabilly et al.
patent: 2006/0018909 (2006-01-01), Oliner et al.
patent: 0 869 180 (1998-10-01), None
patent: 911393 (1999-04-01), None
patent: 0 958 829 (1999-11-01), None
patent: 714912 (2000-05-01), None
patent: 0 526 452 (2001-02-01), None
patent: WO 94/07921 (1994-04-01), None
patent: WO 95/09917 (1995-04-01), None
patent: WO 95/14714 (1995-06-01), None
patent: WO 96/05309 (1996-02-01), None
patent: WO 96/11214 (1996-04-01), None
patent: WO 96/11953 (1996-04-01), None
patent: WO 96/17942 (1996-06-01), None
patent: WO 96/18412 (1996-06-01), None
patent: WO 96/23899 (1996-08-01), None
patent: WO 96/30057 (1996-10-01), None
patent: WO 96/32478 (1996-10-01), None
patent: WO 96/40772 (1996-12-01), None
patent: WO 96/40987 (1996-12-01), None
patent: WO 97/00270 (1997-01-01), None
patent: WO 97/08203 (1997-03-01), None
patent: WO 97/08553 (1997-03-01), None
patent: WO 97/41220 (1997-04-01), None
patent: WO 97/23614 (1997-07-01), None
patent: WO 97/28828 (1997-08-01), None
patent: WO 97/31019 (1997-08-01), None
patent: WO 97/34631 (1997-09-01), None
patent: WO 97/35969 (1997-10-01), None
patent: WO 97/40070 (1997-10-01), None
patent: WO 97/44453 (1997-11-01), None
patent: WO 98/09985 (1998-03-01), None
patent: WO 98/10795 (1998-03-01), None
patent: WO 98/15833 (1998-04-01), None
patent: WO 98/18921 (1998-05-01), None
patent: WO 98/24477 (1998-06-01), None
patent: WO 98/27114 (1998-06-01), None
patent: WO 98/28427 (1998-07-01), None
patent: WO 98/31820 (1998-07-01), None
patent: WO 98/33812 (1998-08-01), None
patent: WO 98/46257 (1998-10-01), None
patent: WO 98/53842 (1998-12-01), None
patent: WO 98/55620 (1998-12-01), None
patent: WO 98/55621 (1998-12-01), None
patent: WO 99/62539 (1999-01-01), None
patent: WO 99/05302 (1999-02-01), None
patent: WO 99/11791 (1999-03-01), None
patent: WO99/12964 (1999-03-01), None
patent: WO 99/14244 (1999-03-01), None
patent: WO 99/17789 (1999-04-01), None
patent: WO 99/18243 (1999-04-01), None
patent: WO 99/18781 (1999-04-01), None
patent: WO 99/24462 (1999-05-01), None
patent: WO 99/25044 (1999-05-01), None
patent: WO 99/35170 (1999-07-01), None
patent: WO 99/42592 (1999-08-01), None
patent: WO 99/47151 (1999-09-01), None
patent: WO 99/50282 (1999-10-01), None
patent: WO 99/51254 (1999-10-01), None
patent: WO 99/60013 (1999-11-01), None
patent: WO 99/61476 (1999-12-01), None
patent: WO 00/00632 (2000-01-01), None
patent: WO 00/01402 (2000-01-01), None
patent: WO 00/04048 (2000-01-01), None
patent: WO 00/11028 (2000-03-01), None
patent: WO 00/24782 (2000-05-01), None
patent: WO 00/40716 (2000-07-01), None
patent: WO 00/47740 (2000-08-01), None
patent: WO 00/67034 (2000-11-01), None
patent: WO 00/68378 (2000-11-01), None
patent: WO 01/02440 (2001-01-01), None
patent: WO 01/85782 (2001-11-01), None
patent: WO 02/16411 (2002-02-01), None
patent: WO 02/16412 (2002-02-01), None
Russell et al, Introduction to phage biology and phage display, 2004, 1-26.
Cwirla et al. (1997), “Peptide Agonist of the Thrombopoietin Receptor as Potent as the Natural Cytokine,”Science276: 1696-1699.
Devlin et al. (1990), “Random Peptide Libraries: A Source of Specific Protein Binding Molecules,”Science249: 404-406.
Gross et al. (2000), “TACI and BCMA are Receptors for a TNF Homologue Implicated in B-cell Autoimmune Disease,”Nature404: 995-999.
Gruss et al. (1995), “Tumor Necrosis Factor Ligand Superfamily: Involvement in the Pathology of Malignant Lymphomas,”Blood85(12): 3378-3404.
Hatzoglou et al. (2000), “TNF Receptor Family Member BCMA (B Cell Maturation) Associates with TNF Receptor-Associated Factor (TRAF)1, TRAF2, and TRAF3 and Activates NF-κB, Elk-1, c-Jun N-Terminal Kinase, and p38 Mitogen-Activiated Protein Kinase,”J. of Immunology165: 1322-1330.
Khare et al. (2000), “Severe B Cell Hyperplasia and Autoimmune Disease in TALL-1 Transgenic Mice,”PNAS97(7):3370-3375.
Lowman (1997), “Bacteriophage Display and Discovery of Peptide Leads for Drug Development,”Ann. Rev. Biophys, Biomol. Struct.26: 401-424.
Roberts & Szostak (1997), “RNA-Peptide Fusions for the in vitro Selection of Peptides and Proteins,”Proc. Natl. Acad. Sci. USA, 94: 12297-12302.
Shu et al. (1999), “TALL-1 is a Novel Member of the TNF Family that is Down-Regulated by Mitogens,”J. Leukocyte Biol.65:680-683.
Shu et al. (2000), “B Cell Maturation Protein is a Receptor for the Tumor Necrosis Factor Family Member TALL-1,”PNAS97(16):9156-9161.
Smith et al. (1994), “The TNF Receptor Superfamily of Cellular and Viral Proteins: Activation, Costimulation, and Death,”Cell76: 959-962.
Takasaki et al. (1997), “Structure-based Design and Characterization of Exocyclic Peptidomimetics that Inhibit TNFα Binding to its Receptor,”Nature Biotech.15: 1266-1270.
Thompson et al. (2000), “BAFF Binds to the Tumor Necrosis Factor Receptor-like Molecule B Cell Maturation Antigen and is Important for Maintaining the Peripheral B Cell Population,”J. Exp. Med.192(1):129-135.
Ware (2000), “April and BAFF Connect Autoimmunity and Cancer,”J. Exp. Med.192(11): F35-F37.
Ware (2000), “Decoy Receptors Thwart B Cells,”Nature404: 949-950.
Xia et al. (2000), “TACI is a TRAF-Interacting Receptor for TALL-1, a Tumor Necrosis Factor Family Member Involved in B Cell Regulation,”J. Exp. Med.192(1):137-143.
Yu et al. (2000), “April and TALL-1 and Receptors BCMA and TACI: System for Regualting Humoral Immunity,”Nature Immunology1(3):252-256.
Tan et al. (2002), “Local Production of B Lymphocyte Stimulator (BlyS™) Protein in Human Arthritic Joints,”abstract.
Cheema et al. (2002), “Increased B Lymphocyte Stimulator (BlyS™) Protein in HIV-Patients: Correlation with Anti-Cardiolipin (aCL) and Anti-Phospholipid (aPL) Autoantibodies,”abstract.
Sekut et al. (2002), “Characterization of a Human Monoclonal Antibody that Antagonizes B-Lymphocyte Stimulator Bioactivies,”abstract.
Zhang et al. (2001), “Cutting Edge: A Role for B Lymphocyte Stimulator in Systemic Lupus Erythematosus,”J. Immunology166:6-10.
Oren et al. (2002), “Structural Basis of BlyS Receptor Recognition,”Nature Structural Biology9(4): 288-292.
Cheema et al. (2001), “Elevated Serum B Lymphocyte Stimulator Levels in Patients With Systemic Immune—Based Rheumatic Diseases,”Arthritis&Rheumatism44(6):1313-1319.
Mukhopadhyay et al. (1999), “Identification and Characterization of a Novel Cytokine, THANK, a TNF Homologue That Activates Apoptosis, Nuclear Factor-κB, and c-June NH2-Terminal Kinase,”J. B

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Modified peptides as therapeutic agents does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Modified peptides as therapeutic agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified peptides as therapeutic agents will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-4072320

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.